Clinical Trial Update: Ultralow Dose PET Imaging of 18F-FDOPA [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ultralow-dose PET imaging with the radiotracer 18F-FDOPA in healthy volunteers and Parkinsonian syndromes to assess dose optimization a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Neuroendocrine Tumors
• Parkinson Disease

Drugs mentioned

• 18F-FDOPA (fluorodopa (18F))

Snippet

Sponsor: Akiva Mintz | Conditions: Heathy Volunteer, Parkinsonian Syndromes | Phase 2 | Status: ENROLLING_BY_INVITATION